Artificial intelligence (AI) algorithms and deep learning continue to change the landscape of radiology. New algorithms promise to enhance diagnostic accuracy, improve workflow efficiency, and automate repetitive tasks. This article provides a narrative review of the FDA-cleared AI algorithms which are commercially available in the United States as of late 2024 and targeted toward assessment of abdominopelvic organs and related diseases, evaluates potential advantages of using AI, and suggests future directions for the field.